Zheng Quan Zhi Xing·2025-08-18 00:28Core Viewpoint - The report highlights the growth potential of Olin Biologicals, particularly in the tetanus vaccine market and the promising development of the pneumococcal vaccine, leading to a "Buy" rating with a target price of 27.09 yuan per share [1][6]. Group 1: Company Overview - Olin Biologicals is a biopharmaceutical company focused on the research, production, and sales of human vaccines, with key products including the adsorbed tetanus vaccine, Hib conjugate vaccine, and AC conjugate vaccine [2]. - The adsorbed tetanus vaccine is the company's core product, contributing nearly 80% of revenue and maintaining a gross margin above 90% [3]. Group 2: Market Potential - The market for the adsorbed tetanus vaccine is expected to grow to 2.4 billion yuan by 2030, driven by supportive policies [3]. - The company is leading globally in the development of the recombinant pneumococcal vaccine, which is currently in Phase III clinical trials, with the potential to fill a significant market gap if successful [4]. Group 3: Research and Development Pipeline - In addition to the pneumococcal vaccine, the company has several other vaccine candidates in development, including oral recombinant Helicobacter pylori vaccine and recombinant Pseudomonas aeruginosa vaccine, all classified as first-in-class drugs [5]. - Successful development of the pneumococcal vaccine could enhance the company's reputation in the antibiotic-resistant vaccine sector and strengthen its long-term competitive position [5]. Group 4: Financial Projections - Revenue projections for the company from 2025 to 2027 are estimated at 647 million, 713 million, and 772 million yuan, respectively, with year-on-year growth rates of 9.80%, 10.27%, and 8.34% [6]. - Net profit attributable to shareholders is forecasted to be 30 million, 44 million, and 66 million yuan for the same period, with corresponding earnings per share of 0.07, 0.11, and 0.16 yuan [6].